Nadian Bio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 6

Nadian Bio General Information

Description

Developer of cancer drugs intended to provide neutropenia medications. The company develops anti-cancer combination therapy, cancer treatment side effects, and aging disease treatment, enabling patients to lower the side effects of drugs and enhance the therapeutic effect of existing drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wonkwang University Incubation Center, 460 Iksan-daero
  • Room 201-1, 4105, 4th Floor, Startup Support Center
  • Iksan, Jeollabuk 54538
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Wonkwang University Incubation Center, 460 Iksan-daero
  • Room 201-1, 4105, 4th Floor, Startup Support Center
  • Iksan, Jeollabuk 54538
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nadian Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 01-Sep-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 20-Aug-2019 $10M $13.4M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 06-Apr-2018 $3.38M $3.38M Completed Clinical Trials - Phase 1
To view Nadian Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nadian Bio Patents

Nadian Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024147659-A1 Composition and soft capsule formulation comprising naphthoquinone-based compound Inactive 05-Jan-2023
JP-2023533187-A A pharmaceutical composition for preventing or treating cancer comprising a naphthoquinone-based compound and an immune checkpoint inhibitor as active ingredients Active 10-Jul-2020
JP-7573657-B2 A pharmaceutical composition for preventing or treating cancer comprising a naphthoquinone-based compound and an immune checkpoint inhibitor as active ingredients Active 10-Jul-2020
AU-2021305584-A1 Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients Pending 10-Jul-2020
AU-2021305584-A8 Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients Pending 10-Jul-2020 A61P35/00
To view Nadian Bio’s complete patent history, request access »

Nadian Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nadian Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cloud IB Venture Capital Minority
DS Asset Management Asset Manager Minority
Jeonbuk Technology Holdings Venture Capital Minority
Korea Development Bank VC-Backed Company Minority
SJ Investment Partners Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Nadian Bio FAQs

  • When was Nadian Bio founded?

    Nadian Bio was founded in 2016.

  • Where is Nadian Bio headquartered?

    Nadian Bio is headquartered in Iksan, South Korea.

  • What is the size of Nadian Bio?

    Nadian Bio has 3 total employees.

  • What industry is Nadian Bio in?

    Nadian Bio’s primary industry is Drug Discovery.

  • Is Nadian Bio a private or public company?

    Nadian Bio is a Private company.

  • What is Nadian Bio’s current revenue?

    The current revenue for Nadian Bio is .

  • How much funding has Nadian Bio raised over time?

    Nadian Bio has raised $22M.

  • Who are Nadian Bio’s investors?

    Cloud IB, DS Asset Management, Jeonbuk Technology Holdings, Korea Development Bank, and SJ Investment Partners are 5 of 6 investors who have invested in Nadian Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process